Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger(Yale Cancer Center), Julie R. Brahmer(Johns Hopkins University), David R. Spigel(Sarah Cannon), Leena Gandhi(Celldex Therapeutics (United States)), Philip D. Leming(Oncology Hematology Care), Matthew D. Hellmann(AstraZeneca (United States)), Vindira Sankar(Bristol-Myers Squibb (Germany)), Scott Antonia(Parker Institute for Cancer Immunotherapy), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Christoph M. Ahlers(Bristol-Myers Squibb (Germany)), Suzanne L. Topalian(Bloomberg (United States)), David P. Carbone(Vanderbilt University), Rebecca S. Heist(Massachusetts General Hospital), Drew M. Pardoll(Bloomberg (United States)), Lecia V. Sequist(Harvard University), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Naiyer A. Rizvi(Synthego (United States)), Mark Salvati(Regeneron (United States)), Georgia Kollia(Bristol-Myers Squibb (United States)), F. Stephen Hodi(Harvard University), Richard D. Carvajal(Northwell Health), John D. Powderly(Carolina BioOncology Institute), Leora Horn(Heidelberg University), David M. Jackman(Brigham and Women's Hospital), Ashok Gupta, Mary Pinder-Schenck(Sarah Cannon), David F. McDermott(Beth Israel Deaconess Medical Center), David C. Smith(University of Michigan), Mario Sznol(Yale University)
Cited by 1,192
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k